- Report
- May 2025
- 180 Pages
Global
From €3165EUR$3,545USD£2,763GBP
€3517EUR$3,939USD£3,069GBP
- Report
- March 2025
- 175 Pages
Global
From €4008EUR$4,490USD£3,499GBP
- Report
- February 2025
- 200 Pages
Global
From €4008EUR$4,490USD£3,499GBP
- Report
- August 2025
- 93 Pages
Global
From €5223EUR$5,850USD£4,559GBP
- Report
- July 2021
- 50 Pages
China
From €2321EUR$2,600USD£2,026GBP
- Report
- May 2024
- 131 Pages
Global
From €5802EUR$6,499USD£5,064GBP
- Report
- July 2024
- 105 Pages
Global
From €4241EUR$4,750USD£3,701GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,200USD£3,162GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,200USD£3,162GBP
- Report
- August 2025
- 50 Pages
Global
From €2366EUR$2,650USD£2,065GBP
- Report
- March 2025
- 215 Pages
China
From €3571EUR$4,000USD£3,117GBP
- Report
- March 2025
- 109 Pages
China
From €1607EUR$1,800USD£1,403GBP
Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more
